Tumor mutational burden predicts the efficacy of pembrolizumab monotherapy: a pan-tumor retrospective analysis of participants with advanced solid tumors

BACKGROUND: Several studies have evaluated the relationship between tumor mutational burden (TMB) and outcomes of immune checkpoint inhibitors. In the phase II KEYNOTE-158 study of pembrolizumab monotherapy for previously treated recurrent or metastatic cancer, high TMB as assessed by the Foundation...

Descripción completa

Detalles Bibliográficos
Autores principales: Cristescu, Razvan, Aurora-Garg, Deepti, Albright, Andrew, Xu, Lei, Liu, Xiao Qiao, Loboda, Andrey, Lang, Lixin, Jin, Fan, Rubin, Eric H, Snyder, Alexandra, Lunceford, Jared
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Immunotherapy Biomarkers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8804694/
https://www.ncbi.nlm.nih.gov/pubmed/35101941
http://dx.doi.org/10.1136/jitc-2021-003091

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8804694/
https://www.ncbi.nlm.nih.gov/pubmed/35101941
http://dx.doi.org/10.1136/jitc-2021-003091

Ejemplares similares